CATX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CATX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Perspective Therapeutics's Trailing 12-Month Free Cash Flow is $-40.59 Mil, and Market Cap is $235.21 Mil. Therefore, Perspective Therapeutics's FCF Yield % for today is -17.26%.
The historical rank and industry rank for Perspective Therapeutics's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Perspective Therapeutics was -1.64%. The lowest was -50.47%. And the median was -12.99%.
Perspective Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.
The historical data trend for Perspective Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Dec23 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial | -19.88 | -10.23 | -2.84 | -18.17 | -33.53 |
Perspective Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
FCF Yield % | Get a 7-Day Free Trial | -53.84 | -32.12 | 2.74 | -5.90 | -11.68 |
For the Medical Devices subindustry, Perspective Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Perspective Therapeutics's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Perspective Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -37.985 | / | 113.28762 | |
= | -33.53% |
Perspective Therapeutics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -26.347 | * | 4 | / | 901.96338 | |
= | -11.68% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perspective Therapeutics FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Perspective Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Johan M. Spoor | director, officer: CEO | 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116 |
Jonathan Robert Hunt | officer: Chief Financial Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Williamson Robert F Iii | director | 140 LASALLE AVENUE, PIEDMONT CA 94610 |
Lori A Woods | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Markus Puhlmann | officer: Chief Medical Officer | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Heidi Henson | director | 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008 |
Frank Morich | director | 40 GUEST STREET, BOSTON MA 02135 |
Mark John Austin | officer: Controller/Prin Fin&Acct Offic | 350 HILLS ST, STE 106, RICHLAND WA 99354 |
Philip J Vitale | director | 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255 |
Michael W Mccormick | director | 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260 |
William Cavanagh | officer: Vice President | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Alan Hoffmann | director | 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032 |
Michael Krachon | officer: VP of Sales & Marketing | 350 HILLS STREET, SUITE 106, RICHLAND WA 99354 |
Krista Cline | officer: Dir. of Operations, Secretary | 350 HILLS STREET, STE 106, RICHLAND WA 99354 |
Jennifer Streeter | officer: VP of Human Resources | 350 HILLS STREET SUITE 106, RICHLAND WA 99354 |
From GuruFocus
By PRNewswire PRNewswire • 01-06-2021
By PRNewswire PRNewswire • 10-28-2022
By GuruFocus Research • 03-30-2024
By GuruFocus Research • 09-23-2024
By Value_Insider Value_Insider • 10-16-2022
By GuruFocus News • 11-12-2024
By PRNewswire PRNewswire • 10-28-2022
By Value_Insider Value_Insider • 11-13-2022
By GuruFocus News • 11-07-2024
By Marketwired Marketwired • 10-29-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.